Introduction to Weight Loss Drug
The US Food and Drug Administration (FDA) has approved a pill version of the weight loss drug Wegovy, made by pharmaceutical giant Novo Nordisk. This marks the first pill of its kind to be approved by regulators, signaling a new era for weight loss drugs.
Approval and Comparison to Existing Treatments
Danish Wegovy maker Novo Nordisk stated that the once-daily pill is a "convenient alternative" to the injectable version and would cause the same weight loss as the injection. This approval comes after Wegovy was specifically approved by the FDA for weight loss, unlike other drugs such as Ozempic, which has similar weight-loss effects but was primarily approved for the treatment of type 2 diabetes.
Clinical Trial Results
The Wegovy pill showed an average weight loss of 16.6% during Novo Nordisk’s trials. A third of the approximately 1,300 participants experienced a weight loss of 20% or more in the same trial.
Market Expectations and Impact on the Company
The pill is expected to hit the U.S. market in early January 2026. According to Mike Doustdar, the company’s chief executive, "Patients will receive a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection." The introduction of the pill version of Wegovy could give Novo Nordisk’s sales a boost after a difficult year in which the company’s shares slumped on profit warnings, facing stiff competition in the weight loss market from rival drugmakers.
Financial Impact
Shares of Novo Nordisk rose nearly 10% in after-hours trading in New York following the announcement, indicating a positive reception of the news by investors. This development is significant for the company as it navigates the competitive landscape of the weight loss drug market.
